Skip To Main Content
Sérgio Leal on Muck Rack

Sérgio Leal

As seen in: Nature, MDPI, Revista Turismo em Análise, Dialnet - Universidad de La Rioja, A Gazeta, Famvin
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sérgio

Contact Sérgio, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Infographic: Efficacy and safety of high-dose intravitreal aflibercept 8 mg in patients with diabetic macular oedema: week 96 results from the phase 2/3 PHOTON trial

|
By Diana V. Do, Sérgio Leal, Alyson J. Berliner
| Nature Verified
Fig. 1 In the phase 2/3 PHOTON trial, aflibercept 8 mg at extended dosing intervals maintained similar visual and anatomic improvements with fewer injections and comparable safety to aflibercept 2 mg every 8 weeks in patients with diabetic macular oedema through Week 96 [1].
Open in Who Shared Issue with article?

Infographic: Efficacy and Safety of HighDdose Intravitreal Aflibercept 8 mg in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Week 96 Results from the Phase 3 PULSAR Trial

|
By Jean-Francois Korobelnik, Sérgio Leal, Paolo Lanzetta
| Nature Verified
Fig. 1 In the phase 3 PULSAR trial, aflibercept 8 mg demonstrated similar visual and anatomic improvements with extended dosing intervals and a similar safety profile to aflibercept 2 mg in patients with neovascular age-related macular degeneration. Funding The PULSAR trial (NCT04423718) was co-funded by Bayer AG, Leverkusen, Germany, and Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Open in Who Shared Issue with article?

Infographic: study design of the QUASAR randomised trial of aflibercept 8 mg in retinal vein occlusion - Eye

|
By Andrew Chang, Sérgio Leal, Lynne R Brunck, Alyson J. Berliner, Fabiana Q. Silva
| Nature Verified
Acknowledgements The authors acknowledge Kushali Patel, PharmD, an employee of Bayer, for medical writing support for the development of this infographic, in accordance with Good Publication Practice guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460). Funding The QUASAR study (NCT05850520) was sponsored by Bayer Consumer Care AG, Basel, Switzerland.
Open in Who Shared Issue with article?
See all 9 licensed articles (11 Total)